AlphaVax, Inc. (AVX, Research Triangle Park, NC), is a privately-held, clinical-stage biopharmaceutical company focused on the development of vaccines for the treatment and management of various cancers.
AVX has successfully progressed the development its proprietary alphavaccine vector technology, to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various cancers. Five alphavaccine candidates have been assessed in clinical trials over the past several years. Results from AVX’s first trial evaluating its CEA alphavaccine for colon cancer in Stage IV patients, showed the vector technology was able to “break self-tolerance” and a trend for enhanced survival in patients with CEA-specific T cell responses. To follow up, AVX will initiate and complete clinical trials in breast cancer, colon cancer (in Stage III patients) and melanoma over the next three years.